Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis

Truncating and missense mutations of the CREBBP gene are highly prevalent in follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancies. These mutations are acquired early during tumor evolution by a common precursor cell (CPC) and lead to either complete protein loss or single amino-acid substitutions in the acetyltransferase (KAT) domain. As a result, CREBBP is impaired in its ability to acetylate enhancer histones and non-histone proteins implicated in the germinal center (GC) reaction, the structure from which these tumors originate. However, whether truncating and KAT domain missense mutations are functionally equivalent in instructing the CPC remains unexplored. Using a conditional GC-specific knock-in mouse model for the highly frequent CREBBP-R1446H amino-acid change (CrebbpRH), here we show that, compared to complete Crebbp loss, missense mutants impose distinct quantitative and qualitative effects on the GC response. CrebbpRH controls unique transcriptional programs leading to the pre-neoplastic expansion of GCs with abnormal architecture, increased percentage of Tfh cells, and a skewed immune response toward memory B-cell differentiation. Expression of CrebbpRH, but not Crebbp loss, was by itself sufficient to initiate malignant transformation, indicating a stronger tumor-promoting activity. Of note, lymphoma cells with CREBBPRH and CREBBP loss showed distinct sensitivity to CREBBP/p300 small molecule inhibitors. Together with the differential distribution of missense and truncating mutations in FL and DLBCL, these findings have implications for the pathogenesis and therapeutic targeting of these cancers.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-02-26
DOI
https://doi.org/10.1182/blood.2025031181
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis

Mara Holloman, Yunchao Chang, Antony B. Holmes, A. K. Kim et al.
Blood
Lymphoma Diagnosis and Treatment
article

Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis

Mara Holloman, Yunchao Chang, Antony B. Holmes, A. K. Kim, Stefanie N. Meyer, Tongwei Mo, Ryan D. Morin, Kostiantyn Dreval, Chuanjiang Yu, Charles G. Mullighan, Riccardo Dalla-Favera, Katia Basso, Laura Pasqualucci, Bowen Cai
article en

Abstract

Truncating and missense mutations of the CREBBP gene are highly prevalent in follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancies. These mutations are acquired early during tumor evolution by a common precursor cell (CPC) and lead to either complete protein loss or single amino-acid substitutions in the acetyltransferase (KAT) domain. As a result, CREBBP is impaired in its ability to acetylate enhancer histones and non-histone proteins implicated in the germinal center (GC) reaction, the structure from which these tumors originate. However, whether truncating and KAT domain missense mutations are functionally equivalent in instructing the CPC remains unexplored. Using a conditional GC-specific knock-in mouse model for the highly frequent CREBBP-R1446H amino-acid change (CrebbpRH), here we show that, compared to complete Crebbp loss, missense mutants impose distinct quantitative and qualitative effects on the GC response. CrebbpRH controls unique transcriptional programs leading to the pre-neoplastic expansion of GCs with abnormal architecture, increased percentage of Tfh cells, and a skewed immune response toward memory B-cell differentiation. Expression of CrebbpRH, but not Crebbp loss, was by itself sufficient to initiate malignant transformation, indicating a stronger tumor-promoting activity. Of note, lymphoma cells with CREBBPRH and CREBBP loss showed distinct sensitivity to CREBBP/p300 small molecule inhibitors. Together with the differential distribution of missense and truncating mutations in FL and DLBCL, these findings have implications for the pathogenesis and therapeutic targeting of these cancers.

Blood
St. Jude Children's Research Hospital (US), Simon Fraser University (CA), Regeneron (United States) (US), Saint Louis University (US), Columbia University (US)
Good health and well-being
Openalex Percentile: Top 43%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.